ICHNO-ECHNO 2022 - Abstract Book

S42

ICHNO-ECHNO 2022

(P<0.001). Multivariate analysis confirmed the significant association with age, tumor stage and treatment (P<0.01). HPV was positive in 10 cases (3.5%) mostly in the oropharynx (21%) and showed higher survival. Conclusion This study indicates an overall low prevalence of HPV infection in our HNSCC patients. Although oropharyngeal cancer cases were infrequent, they increased over years and 21% were associated with HPV infection. Age, smoking, tumor stage, and treatment had important effect on survival. HPV-positivity had more favorable treatment outcome The stratification according to HPV (and possibly p16) status could improve prognosis’ prediction by distinguishing between the more favorable HPV-positive from the less favorable HPV-negative patients. To confirm this prediction, more oropharyngeal cancer patients are being included in this ongoing study.

PO-0075 Prognos & Risk Grouping in P16+/- Oropharynx Carcinoma: TROD (Turkish Radiation Oncology) 01-002

Abstract withdrawn

PO-0076 Evolution from 2011 to 2020 of HPV oropharynx carcinoma population in a major French cancer center

P. Gorphe 1 , M. Classe 2 , P. Blanchard 3 , O. Casiraghi 2 , S. Temam 1

1 Gustave Roussy, Head and Neck Oncology, Villejuif, France; 2 Gustave Roussy, Pathology, Villejuif, France; 3 Gustave Roussy, Radiation Oncology, Villejuif, France Purpose or Objective The rising incidence of HPV-driven oropharyngeal carcinoma (OPC) has been reported in Sweden and in the USA, concomitant with the decreasing incidence of HPV-negative OPC, resulting in a high increase of the prevalence of HPV- positive tumors among OPC. There is no available data on the evolution of HPV-driven oropharyngeal carcinoma in France, and published prevalence rates have been 33.2% of HPV PCR DNA-positive OPC in the Papillophar study among xxx patients from 2009 to 2012 and 43.1% of p16-positive OPC in a multicentric study among xxx patients from 2011 to 2012. We hypothesized that the prevalence of HPV-driven OPC increased in the last decade in France, and that it resulted in significant demographic changes in the oropharyngeal cancer population. Materials and Methods All patients with an OPC treated at our center between the first of January, 2011, to the 31 st of December, 2020, were reviewed for clinical and demographic characteristics, p16 expression status and HPV HIS DNA status, smoking habits, 8ed TNM disease staging, treatments, and survival. P16-positive and negative populations were compared, and evolution of characteristics in time were analyzed. Survival of OPC populations were compared between 2011-2015 and 2016-2020? Results 1230 OPC patients were treated at our center during this period of time, with an homogeneous number of patients per year. Of note, at our center 55% of head and neck cancer patients come from Grand Paris-Ile de France, while 45% come the rest of France. 23.1% of OPC pts were women, and this rate remained stable during the decade. 528 pts were p16- positive, and the prevalence of p16-positive status increased linearly from 34.3% in 2011 to 52.6% in 2020. The HIS HPV DNA status was available for 371 pts, and was positive in 87.3%, a rate that that remained stable during the decade. The mean ages were 61.8y and 61.5y in p16-pos and p16-neg pts (p=0.69) and both rised almost linearly during the decade from 60y to 64y. However, age distribution were not similar, with more spread age pyramid in p16-positive pts (p=0.03). the rate of stage III disease increased to 39% in 2020, while the rate of stage IV disease decreased to 37%. The 2-y and 5-y survival were 76.4% and 60.3% in the global cohort, and the 2-y survival slightly increased from 75.4% to 77.2% (p=0.15). Conclusion In the last decade, the prevalence of HPV-driven tumors among patients with oropharyngeal carcinoma increased from 34% to 53% at our large-scale center. This change resulted in significant demographic evolutions in OPC population, that may continue to evolve in the future decade. M. Elsharief 1 , B. Fortin 2 , P.F. Nguyen-Tan 3 , E. Filion 3 , C. Larose 4 , L. Seddik 3 , D. Soulieres 5 , A. Christopoulos 6 , L. Guertin 6 , T. Ayad 7 , E. Bissada 6 , J. Tabet 6 , H. Bahig 8 1 Centre Hospitalier de l'Université de Montréal, Radiation Oncology departement , Montreal, Canada; 2 Hopital Maisonneuve Rosemont, Radiation Oncology departement , Montreal , Canada; 3 Centre Hospitalier de l'Université de Montréal, Radiation Oncology departement , Montreal , Canada; 4 Centre Hospitalier Charles Lemoyne, Department of Otolaryngology, Montreal , Canada; 5 Centre Hospitalier de l'Université de Montréal, Department of Hemato-oncology, Montreal , Canada; 6 Centre Hospitalier de l'Université de Montréal, Department of Otolaryngology, Montreal , Canada; 7 Centre Hospitalier de l'Université de Montréal, Department of Otolaryngology, Montreal , Canada; 8 Centre Hospitalier de l'Université de Montréal, Radiation Oncology departement, Montreal , Canada Purpose or Objective To report treatment outcome of patients with oropharyngeal cancer (OPC) treated with curative intent modern radiotherapy and to determine predictive factors of hospitalistion and severe late toxicity PO-0077 Factors predictive of per-treatment hospitalization and late toxicity in oropharyngreal cancer